Charles River Laboratories Intl (CRL) 84.42 $CRL
Post# of 273257
Posted On: 09/05/2016 1:06:03 AM
Charles River Laboratories Intl (CRL) 84.42 $CRL
Charles River Laboratories Announces Partnership with the Milner Therapeutics Institute and Consortium
BusinessWire - Mon Aug 08, 3:30PM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with the Milner Therapeutics Institute and Consortium.
GSK: 44.26 (+1.28), CRL: 84.42 (+0.82)
Charles River Laboratories Announces Second-Quarter 2016 Results from Continuing Operations
BusinessWire - Wed Aug 03, 6:00AM CDT
--- Second-Quarter GAAP Earnings per Share of $0.73
CRL: 84.42 (+0.82)
Healthcare Q2 Earnings Lineup for Aug 3: HUM, CRL & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:36AM CDT
The Medical sector is expected to deliver 5.4% earnings growth on 10.5% higher revenues in the second quarter.
PRXL: 68.70 (+0.36), EVHC: 22.18 (+0.73), CRL: 84.42 (+0.82), HUM: 177.33 (+0.80)
Charles River Laboratories to Present at Jefferies and William Blair Conferences
BusinessWire - Mon Jun 06, 7:30AM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Jefferies 2016 Global Healthcare Conference in New York, New York on Wednesday, June 8th, at 10:00 a.m. EDT, and the William Blair 36th Annual Growth Stock Conference in Chicago, Illinois on Tuesday, June 14th, at 1:30 p.m. CDT (2:30 p.m. EDT). Management will present an overview of Charles River's strategic focus and business developments.
CRL: 84.42 (+0.82)
Moderna Therapeutics and Charles River Laboratories Announce Strategic Collaboration to Scale Moderna's Nonclinical Development Efforts for Novel mRNA Therapeutics
BusinessWire - Mon Jun 06, 7:00AM CDT
Moderna Therapeutics, a clinical stage pioneer in the development of messenger RNA (mRNA) Therapeutics(TM) and Charles River Laboratories International, Inc. (NYSE:CRL), a leading early-stage contract research organization (CRO), today announced a strategic collaboration to support Moderna's nonclinical discovery and development efforts. Charles River will be a key partner as Moderna continues to grow and advance its pipeline spanning multiple drug modalities and therapeutic areas, conducting nonclinical activities to progress development candidates through investigational new drug (IND)-enabling studies and into the clinic.
CRL: 84.42 (+0.82)
Charles River beats Street 1Q forecasts
Automated Insights - Wed May 04, 6:20AM CDT
WILMINGTON, Mass. (AP) _ Charles River Laboratories International Inc. (CRL) on Wednesday reported first-quarter earnings of $37.1 million.
CRL: 84.42 (+0.82)
Charles River Laboratories Announces First-Quarter 2016 Results from Continuing Operations
BusinessWire - Wed May 04, 6:00AM CDT
--- First-Quarter GAAP Earnings per Share of $0.78and Non-GAAP Earnings per Share of $0.98 -
CRL: 84.42 (+0.82)
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Molina Healthcare, PAREXEL International, Air Methods and Charles River Laboratories International
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:30AM CDT
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Molina Healthcare, PAREXEL International, Air Methods and Charles River Laboratories International
AIRM: 35.79 (+0.90), PRXL: 68.70 (+0.36), EBS: 26.90 (+0.49), CRL: 84.42 (+0.82), MOH: 55.33 (+1.79)
5 Stocks to Invest on Healthcare Rebound
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 10:42AM CDT
Healthcare stocks bounced back this month after being mostly out of favor during the first quarter.
AIRM: 35.79 (+0.90), PRXL: 68.70 (+0.36), EBS: 26.90 (+0.49), CRL: 84.42 (+0.82), MOH: 55.33 (+1.79)
Charles River Laboratories Schedules First-Quarter 2016 Earnings Release and Conference Call
BusinessWire - Thu Apr 07, 3:30PM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2016 financial results on Wednesday, May 4th before the market opens. A conference call has been scheduled to discuss this information on Wednesday, May 4th, at 8:30 a.m. ET.
CRL: 84.42 (+0.82)
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2015 Results from Continuing Operations and Provides 2016 Guidance
BusinessWire - Wed Feb 10, 6:00AM CST
--- Fourth-Quarter GAAP Earnings per Share of $0.69 and Non-GAAP Earnings per Share of $1.00 -
CRL: 84.42 (+0.82)
PAREXEL International Q2 Earnings Beat, FY16 View Slashed
Zacks Equity Research - Zacks Investment Research - Thu Jan 28, 8:00AM CST
PAREXEL International Corp (PRXL) reported adjusted earnings of 90 cents per share in the second quarter of fiscal 2016, beating the Zacks Consensus Estimate by 19 cents.
PRXL: 68.70 (+0.36), INCR: 44.01 (+0.19), AHS: 36.25 (+0.57), CRL: 84.42 (+0.82)
Zacks Investment Ideas feature highlights: AMN Healthcare Services, Charles River Lab, Healthways, INC Research and Air Methods
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 8:30AM CST
Zacks Investment Ideas feature highlights: AMN Healthcare Services, Charles River Lab, Healthways, INC Research and Air Methods
AIRM: 35.79 (+0.90), INCR: 44.01 (+0.19), HWAY: 24.96 (+0.10), AHS: 36.25 (+0.57), CRL: 84.42 (+0.82)
Top Healthcare Stocks
Brian Bolan - ZACKS - Thu Jan 21, 2:17PM CST
Top Healthcare Stocks
AIRM: 35.79 (+0.90), HWAY: 24.96 (+0.10), INCR: 44.01 (+0.19), AHS: 36.25 (+0.57), CRL: 84.42 (+0.82)
Charles River Laboratories Schedules Fourth-Quarter 2015 Earnings and 2016 Guidance Release and Conference Call
BusinessWire - Wed Jan 20, 3:30PM CST
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2015 financial results and provide 2016 guidance on Wednesday, February 10th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 10th, at 8:30 a.m. ET.
CRL: 84.42 (+0.82)
New Strong Buy Stocks for January 19th
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
CNC: 68.62 (+1.28), CBG: 30.17 (+0.28), AAL: 36.53 (+0.29), CRL: 84.42 (+0.82), CAFD: 15.56 (+0.01)
Upgrade Alert for Charles River Laboratories (CRL)
Comtex SmarTrend(R) - Fri Jan 08, 7:15AM CST
Charles River Laboratories (NYSE:CRL) was upgraded from Market Perform to Outperform at Wells Fargo today. The stock closed yesterday at $78.52 on volume of 1.2 million shares, above average daily volume of 389,000. Based on a current price of $78.52, Charles River Laboratories is currently 0.4% above its average consensus analyst price target of $78.21. The stock should find initial support at its 50-day moving average (MA) of $75.24 and further support at its 200-day MA of $72.90.
CRL: 84.42 (+0.82)
BUYINS.NET: CVV, ISRG, CCG, RUSHA, CRL, CIU Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri Jan 08, 6:38AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Canalaska Uranium Ltd (NASDAQ:CVV), Intuitive Surgical Inc (NASDAQ:ISRG), Campus Crest Communities Inc (NYSE:CCG), Rush Enterprises Inc (NASDAQ:RUSHA), CHARLES RIVER LABORATORIES INTERNATIONAL INC (NYSE:CRL), Ishares Barclays Intermediate Credit Bond Fund (NYSE:CIU) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ISRG: 688.37 (-1.32), CVV: 8.58 (+0.06), CRL: 84.42 (+0.82), RUSHB: 23.75 (-0.28), CIU: 111.29 (+0.02), RUSHA: 23.54 (+0.07), CCG: 7.00 (unch)
Charles River Laboratories Announces Partnership with the Milner Therapeutics Institute and Consortium
BusinessWire - Mon Aug 08, 3:30PM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with the Milner Therapeutics Institute and Consortium.
GSK: 44.26 (+1.28), CRL: 84.42 (+0.82)
Charles River Laboratories Announces Second-Quarter 2016 Results from Continuing Operations
BusinessWire - Wed Aug 03, 6:00AM CDT
--- Second-Quarter GAAP Earnings per Share of $0.73
CRL: 84.42 (+0.82)
Healthcare Q2 Earnings Lineup for Aug 3: HUM, CRL & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:36AM CDT
The Medical sector is expected to deliver 5.4% earnings growth on 10.5% higher revenues in the second quarter.
PRXL: 68.70 (+0.36), EVHC: 22.18 (+0.73), CRL: 84.42 (+0.82), HUM: 177.33 (+0.80)
Charles River Laboratories to Present at Jefferies and William Blair Conferences
BusinessWire - Mon Jun 06, 7:30AM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Jefferies 2016 Global Healthcare Conference in New York, New York on Wednesday, June 8th, at 10:00 a.m. EDT, and the William Blair 36th Annual Growth Stock Conference in Chicago, Illinois on Tuesday, June 14th, at 1:30 p.m. CDT (2:30 p.m. EDT). Management will present an overview of Charles River's strategic focus and business developments.
CRL: 84.42 (+0.82)
Moderna Therapeutics and Charles River Laboratories Announce Strategic Collaboration to Scale Moderna's Nonclinical Development Efforts for Novel mRNA Therapeutics
BusinessWire - Mon Jun 06, 7:00AM CDT
Moderna Therapeutics, a clinical stage pioneer in the development of messenger RNA (mRNA) Therapeutics(TM) and Charles River Laboratories International, Inc. (NYSE:CRL), a leading early-stage contract research organization (CRO), today announced a strategic collaboration to support Moderna's nonclinical discovery and development efforts. Charles River will be a key partner as Moderna continues to grow and advance its pipeline spanning multiple drug modalities and therapeutic areas, conducting nonclinical activities to progress development candidates through investigational new drug (IND)-enabling studies and into the clinic.
CRL: 84.42 (+0.82)
Charles River beats Street 1Q forecasts
Automated Insights - Wed May 04, 6:20AM CDT
WILMINGTON, Mass. (AP) _ Charles River Laboratories International Inc. (CRL) on Wednesday reported first-quarter earnings of $37.1 million.
CRL: 84.42 (+0.82)
Charles River Laboratories Announces First-Quarter 2016 Results from Continuing Operations
BusinessWire - Wed May 04, 6:00AM CDT
--- First-Quarter GAAP Earnings per Share of $0.78and Non-GAAP Earnings per Share of $0.98 -
CRL: 84.42 (+0.82)
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Molina Healthcare, PAREXEL International, Air Methods and Charles River Laboratories International
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:30AM CDT
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Molina Healthcare, PAREXEL International, Air Methods and Charles River Laboratories International
AIRM: 35.79 (+0.90), PRXL: 68.70 (+0.36), EBS: 26.90 (+0.49), CRL: 84.42 (+0.82), MOH: 55.33 (+1.79)
5 Stocks to Invest on Healthcare Rebound
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 10:42AM CDT
Healthcare stocks bounced back this month after being mostly out of favor during the first quarter.
AIRM: 35.79 (+0.90), PRXL: 68.70 (+0.36), EBS: 26.90 (+0.49), CRL: 84.42 (+0.82), MOH: 55.33 (+1.79)
Charles River Laboratories Schedules First-Quarter 2016 Earnings Release and Conference Call
BusinessWire - Thu Apr 07, 3:30PM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2016 financial results on Wednesday, May 4th before the market opens. A conference call has been scheduled to discuss this information on Wednesday, May 4th, at 8:30 a.m. ET.
CRL: 84.42 (+0.82)
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2015 Results from Continuing Operations and Provides 2016 Guidance
BusinessWire - Wed Feb 10, 6:00AM CST
--- Fourth-Quarter GAAP Earnings per Share of $0.69 and Non-GAAP Earnings per Share of $1.00 -
CRL: 84.42 (+0.82)
PAREXEL International Q2 Earnings Beat, FY16 View Slashed
Zacks Equity Research - Zacks Investment Research - Thu Jan 28, 8:00AM CST
PAREXEL International Corp (PRXL) reported adjusted earnings of 90 cents per share in the second quarter of fiscal 2016, beating the Zacks Consensus Estimate by 19 cents.
PRXL: 68.70 (+0.36), INCR: 44.01 (+0.19), AHS: 36.25 (+0.57), CRL: 84.42 (+0.82)
Zacks Investment Ideas feature highlights: AMN Healthcare Services, Charles River Lab, Healthways, INC Research and Air Methods
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 8:30AM CST
Zacks Investment Ideas feature highlights: AMN Healthcare Services, Charles River Lab, Healthways, INC Research and Air Methods
AIRM: 35.79 (+0.90), INCR: 44.01 (+0.19), HWAY: 24.96 (+0.10), AHS: 36.25 (+0.57), CRL: 84.42 (+0.82)
Top Healthcare Stocks
Brian Bolan - ZACKS - Thu Jan 21, 2:17PM CST
Top Healthcare Stocks
AIRM: 35.79 (+0.90), HWAY: 24.96 (+0.10), INCR: 44.01 (+0.19), AHS: 36.25 (+0.57), CRL: 84.42 (+0.82)
Charles River Laboratories Schedules Fourth-Quarter 2015 Earnings and 2016 Guidance Release and Conference Call
BusinessWire - Wed Jan 20, 3:30PM CST
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2015 financial results and provide 2016 guidance on Wednesday, February 10th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 10th, at 8:30 a.m. ET.
CRL: 84.42 (+0.82)
New Strong Buy Stocks for January 19th
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
CNC: 68.62 (+1.28), CBG: 30.17 (+0.28), AAL: 36.53 (+0.29), CRL: 84.42 (+0.82), CAFD: 15.56 (+0.01)
Upgrade Alert for Charles River Laboratories (CRL)
Comtex SmarTrend(R) - Fri Jan 08, 7:15AM CST
Charles River Laboratories (NYSE:CRL) was upgraded from Market Perform to Outperform at Wells Fargo today. The stock closed yesterday at $78.52 on volume of 1.2 million shares, above average daily volume of 389,000. Based on a current price of $78.52, Charles River Laboratories is currently 0.4% above its average consensus analyst price target of $78.21. The stock should find initial support at its 50-day moving average (MA) of $75.24 and further support at its 200-day MA of $72.90.
CRL: 84.42 (+0.82)
BUYINS.NET: CVV, ISRG, CCG, RUSHA, CRL, CIU Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri Jan 08, 6:38AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Canalaska Uranium Ltd (NASDAQ:CVV), Intuitive Surgical Inc (NASDAQ:ISRG), Campus Crest Communities Inc (NYSE:CCG), Rush Enterprises Inc (NASDAQ:RUSHA), CHARLES RIVER LABORATORIES INTERNATIONAL INC (NYSE:CRL), Ishares Barclays Intermediate Credit Bond Fund (NYSE:CIU) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ISRG: 688.37 (-1.32), CVV: 8.58 (+0.06), CRL: 84.42 (+0.82), RUSHB: 23.75 (-0.28), CIU: 111.29 (+0.02), RUSHA: 23.54 (+0.07), CCG: 7.00 (unch)
(0)
(0)Scroll down for more posts ▼